Skip to main content

Cronos Group Inc.

corporate_fare Company Profile

Cronos Group Inc.

CRON·NASDAQ·Life Sciences·CIK 0001656472

General Cronos is a global cannabinoid company focused on developing intellectual property through cannabis research, technology, and product development. The company aims to build a portfolio of brands that enhance the consumer experience. Its international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™, and Lord Jones®. Cronos operates as one consolidated business segment, with operations in both Canada and Israel. In Canada, Cronos operates Peace Naturals Project Inc., a wholly owned license holder under the Cannabis Act (Canada), with production facilities in Stayner, Ontario, known as the Peace Naturals Campus. Cronos also holds a 50% equity interest in Cronos GrowCo, whose production facilities, licensed under the Cannabis Act, are the company's primary source of cannabis. In Israel, Cronos operates with certifications for Good Agricultural Practices (IMC-GAP), Good Manufacturing Practices (IMC-GMP), and Good Distribution Practices (IMC-GDP). These certifications are required for the cultivation, production, distribution, and marketing of medical cannabis products within Israel. General Cronos is incorporated under the laws of the Province of British Columbia, with principal executive offices in Stayner, Ontario. Its common shares are listed on the Toronto Stock Exchange (TSX) and the NASDAQ Global Market (Nasdaq) under the trading symbol "CRON."

Cronos Group Inc. (NASDAQ:CRON) is a publicly traded company in the Life Sciences sector. Wiseek monitors CRON SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Cronos Expands $50M Share Buyback Program to Toronto Stock Exchange, Secures US Trading Exemption
  • Cronos Group Reports Strong Q1 Results, Initiates New $50M Share Buyback, Benefits from US Cannabis Rescheduling
  • Cronos Group Reports Strong Q1 Results, Authorizes $50M Share Buyback
  • Cronos Group Reports Strong Financial Turnaround, Announces Strategic Dutch Acquisition, and Resolves Israeli Anti-Dumping Case
  • Cronos Group Reports Strong Q4/FY 2025 Results and Strategic European Acquisition

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$146.59M
Net Income
-$9.45M
Diluted EPS
-$0.02
Op. Cash Flow
$25.87M
Free Cash Flow
$149K
Gross Profit
$62.76M
Operating Income
-$17.39M
Cash & Equivalents
$791.79M
Debt / Equity
0.00×
Net Margin
-6.4%
Shares Outstanding
381.59M sh
Source: 10-K · filed 2026-02-26 · accession 0001656472-26-000016
Browse all tickers starting with C →
$2.85 -0.01% today
52-week range · as of 2026-05-11 $1.84 – $3.43
Market cap
$1.06B
Volume
828.2K (0.9× avg)
3-mo avg 892.5K
Live data · 2026-07-29 09:32 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed CRON - Latest Insights

CRON
Jun 16, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.64
Real-time Price: $2.85 info
Change: +$0.210 (+8%) info
Market Cap: $1.065B info
CRON
May 11, 2026, 7:33 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.69
Real-time Price: $2.85 info
Change: +$0.160 (+6%) info
Market Cap: $1.065B info
CRON
May 11, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.69
Real-time Price: $2.85 info
Change: +$0.160 (+6%) info
Market Cap: $1.065B info
CRON
Feb 26, 2026, 7:38 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.70
Real-time Price: $2.85 info
Change: +$0.150 (+6%) info
Market Cap: $1.065B info
CRON
Feb 26, 2026, 7:36 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.70
Real-time Price: $2.85 info
Change: +$0.150 (+6%) info
Market Cap: $1.065B info